comparison of academic vs community and Canadian vs agents such as the bisphosphonates when using cortico- with long-term problems.
3. Jansen TLThA, Laan RFJM, Van Riel PLCM.
In conclusion, the discussion on the efficacy and 
FROM CRITICISM TO CREATIVITY: THE GENESIS OF THE ARC/BSR CLINICAL TRIALS GROUP
M of us suffer the pressures of working in isolation, research on a multicentre basis, with a national direction. The ultimate objective is to enable the clinicians and regularly contemplate the nature of the evidence which drives our clinical practice. The bench-mark for throughout the UK to network together and participate in clinical trials relevant to the spectrum of evaluation of management strategies in clinical medicine is the randomized controlled trial, and ideas for rheumatic diseases both common and rare. The product of these deliberations was the ARC/BSR Clinical such trials regularly arise during busy clinical practice. However, the translation from these ideas to the design, Trials Group, which has now been 'pump-primed' with a £1.5 million budget from the ARC. execution, analysis and publication of the finished product is a difficult task, and one where the busy
We believe that the current membership of the group incorporates the appropriate expertise, including clinician is limited by lack of time, resources, and a supporting infrastructure-a view eloquently expressed clinical trials methodology, health services research and rheumatology, in order to set up and oversee by Professor Ian Haslock in a letter to the British Journal of Rheumatology [1] . the venture. All members of the BSR will shortly receive a letter This cri de coeur initiated a series of debates within the Research Subcommittee and Scientific Cooutlining the purpose of the group and how it will facilitate multicentre trials. A request will be made for ordinating Committee of the Arthritis Research Campaign, leading to the formation of an ARC Think members to define two key questions which need to be addressed in rheumatological practice and to provide Tank on clinical trials. This group took advice from many sources, including members of the Medical an outline proposal giving brief details of the objectives, methodology and background. Proposals received Research Council who have considerable expertise in multicentred randomized trials and now an accepted will be prioritized using a Delphi approach (the postal request for questions followed by an analysis of the base for much of haematological and oncological practice.
complete response after anonymization), followed by a nominal group process involving the ARC/BSR In recognition of the difficulties encountered by the clinical rheumatologists in the UK, a combined Clinical Trials Committee in which an explicit ranking of proposals will be undertaken. It is envisaged that response from the ARC and BSR led to the evolution of a structure of support incorporating the skills of 2-3 programmes will be supported during 1999. When the programmes have been identified, the group will relevant professional bodies to promote clinical provide active support facilitating the integration of promote the highest quality of care to rheumatology patients. investigators and defining key investigators who will drive each proposal. The BSR in particular will assist relevant research in our speciality. We encourage you R to take part in this important venture, which we believe will benefit the busy clinician and our speciality,
